Old Web
English
Sign In
Acemap
>
authorDetail
>
Don Sun
Don Sun
Janssen Pharmaceutica
Medicine
Type 2 diabetes
Type 2 Diabetes Mellitus
Internal medicine
Database
4
Papers
30
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.
2021
Annals of Internal Medicine
Rao N.V.S. Mamidi
Damayanthi Devineni
Don Sun
Yshai Yavin
Norman Rosenthal
Show All
Source
Cite
Save
Citations (0)
Abstract 24: Diabetic Ketoacidosis in Patients with Type 2 Diabetes Treated with Sodium Glucose Co-transporter 2 Inhibitors versus Other Antihyperglycemic Agents: An Observational Study of Four US Administrative Claims Databases
2019
Circulation-cardiovascular Quality and Outcomes
Lu Wang
Erica A. Voss
James Weaver
Laura Hester
Zhong Yuan
Frank J. DeFalco
Martijn J. Schuemie
Patrick B. Ryan
Don Sun
Amy Freedman
Maria Alba
Joan Lind
Gary Meininger
Jesse A. Berlin
Norman Rosenthal
Show All
Source
Cite
Save
Citations (0)
Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases
2019
Pharmacoepidemiology and Drug Safety
Lu Wang
Erica A. Voss
James Weaver
Laura Hester
Zhong Yuan
Frank J. DeFalco
Martijn J. Schuemie
Patrick B. Ryan
Don Sun
Amy Freedman
Maria Alba
Joan Lind
Gary Meininger
Jesse A. Berlin
Norman Rosenthal
Show All
Source
Cite
Save
Citations (10)
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
2017
Diabetes, Obesity and Metabolism
Mehul Desai
Yshai Yavin
Dainius Balis
Don Sun
John Xie
William Canovatchel
Norm Rosenthal
Show All
Source
Cite
Save
Citations (20)
1